Mylan Plans Workforce Reduction After M&A And Price Scandal
Executive Summary
Mylan said it expects to cut less than 10% of its workforce under a restructuring to streamline operations following a series of acquisitions. The news comes amid a spate of negative publicity for the company, including a $465m settlement with the US Department of Justice over EpiPen.
You may also be interested in...
Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
The generic drug company will drive mid-term growth by investing in high-barrier-to-entry generics and biosimilars while diversifying into brand medicines and over-the-counter drugs. Management presented a strategy overview during an investor day March 1.
Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
The generic drug company will drive mid-term growth by investing in high-barrier-to-entry generics and biosimilars while diversifying into brand medicines and over-the-counter drugs. Management presented a strategy overview during an investor day March 1.
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
The $50m deal adds a homeopathic brand to Mylan's portfolio that will lead its US consumer lineup; ProPhase will focus on dietary supplements; leave behind seasonal-demand products.